Wockhardt Ltd.
Q4FY23 Quarterly & FY23 Annual Result Announced for Wockhardt Ltd.
Pharmaceuticals company Wockhardt announced Q4FY23 & FY23 results:
- Q4FY23:
- The Company recorded a Revenue of Rs 710 crore in Q4FY23 vs Rs 666 crore in Q4FY22, up 7%
- EBITDA for Q4FY23 is Rs 47 crore as compared to Rs (22) crore in Q4FY22 registering a substantial growth of 314%
- UK Business stood at Rs 242 crore in Q4FY23 compared to Rs 223 crore in Q3FY23 registering a growth of 8%. UK Business contributed about 36% of Global Revenue.
- India Business stood at Rs 125 crore in Q4FY23. India's Business contributed 19% of the Global Revenue.
- Emerging Markets Business of the Company stood at Rs 173 crore in Q4FY23 compared to Rs 148 crore in Q3FY23 registering a growth of 16%. Emerging Markets Business contributed about 25% of the Global Revenue.
- Irish Business stood at Rs 44 crore in Q4FY23 compared to Rs 40 crore in Q3FY23 showing a growth of 10%.
- US Business stood at Rs 50 crore in Q4FY23. US Business contributed 7% of the Global Revenue.
- FY23:
- UK Business stood at Rs 887 crore in FY23. UK Business contributed about 33% of Global Revenue.
- India's Business stood at Rs 609 crore in FY23. India's Business contributed 23% of the Global Revenue.
- Emerging Markets Business of the Company stood at Rs 555 crore in FY23. Emerging Markets Business contributed about 21% of the Global Revenue.
- Irish Business stood at Rs 158 crore in FY23 compared to Rs 153 crore in FY22, up 4%
- US Business stood at Rs 303 crore in FY23. US Business contributed 11% of the Global Revenue.